EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rational Design, Synthesis, Biological Evaluation, and In Silico Study of N ‐Cinnamamide/Benzamide‐(4‐(Substituted Phenyl)‐6‐(4‐Cyclohexylphenyl)pyrimidin‐2‐yl) Derivatives as EGFR Inhibitors Targeting EGFR WT , EGFR T790M , and EGFR L858R / T790M / C797S in NSCLC

Rohit Pal iD, Gurubasavaraja Swamy Purawarga Matada iD, Ghanshyam Teli iD, Manjushree Bv iD, Anguraj Moulishankar iD, Viney Chawla iD, Pooja A Chawla iD

Chemical Biology & Drug Design · 2026

DOI: 10.1111/cbdd.70390 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2026. Verfasst von Rohit Pal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Integrated Drug Discovery Centre, Acharya & BM Reddy College of Pharmacy, Bengaluru, Karnataka, India. Hauptthemen laut MEDLINE: Drug Design, Protein Kinase Inhibitors, Antineoplastic Agents, Benzamides. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non‐small cell lung cancer (NSCLC), driven by mutations in the epidermal growth factor receptor (EGFR), presents significant therapeutic challenges, particularly due to drug resistance. This study describes the design, synthesis, and evaluation of a series of novel N ‐Cinnamamide/benzamide‐(4‐(substituted phenyl)‐6‐(4‐cyclohexylphenyl)pyrimidin‐2‐yl) derivatives ( Ri–Rxii ) as EGFR inhibitors. Among these, compound Riv exhibited superior antiproliferative activity against wild‐type and mutant EGFR‐driven NSCLC cell lines, including EGFR L858R/T790M and the drug‐resistant EGFR L858R/T790M/C797S variant, with low IC 50 values and minimal cytotoxicity towards normal cell lines. Compound Riv effectively induced cell cycle arrest at the S and G2/M phases and triggered apoptosis, with 54.38% of cells undergoing apoptotic or necrotic death. Additionally, Riv exhibited strong antioxidant activity, outperforming the standard ascorbic acid in DPPH and ABTS assays, indicating its ability to reduce oxidative stress. Molecular docking and dynamic simulation studies confirmed stable binding interactions with key EGFR residues, and DFT analysis revealed favorable electronic properties. Furthermore, in silico ADMET predictions highlighted Riv 's promising pharmacokinetic and toxicity profiles, supporting its potential as a safe and effective anticancer agent. This comprehensive evaluation positions Riv as a strong candidate for overcoming drug resistance in NSCLC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignProtein Kinase InhibitorsAntineoplastic AgentsBenzamidesCinnamatesPyrimidinesHumansErbB ReceptorsCarcinoma, Non-Small-Cell LungCell Line, TumorMolecular Docking SimulationLung NeoplasmsApoptosisCell ProliferationMutationTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

ADMETEGFRdockinglung cancerpyrimidine

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsAntineoplastic AgentsBenzamidesEGFR protein, humanCinnamatesPyrimidinescinnamamideTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Integrated Drug Discovery Centre, Acharya & BM Reddy College of Pharmacy, Bengaluru, Karnataka, India.
  • School of Pharmacy, Sangam University, Bhilwara, Rajasthan, India.
  • University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Faridkot, Punjab, India.

ORCID-Profile: Rohit Pal, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli, Manjushree Bv, Anguraj Moulishankar, Viney Chawla, Pooja A Chawla

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Pal, R., Matada, G. S. P., Teli, G., Bv, M., Moulishankar, A., Chawla, V., & Chawla, P. A. (2026). Rational Design, Synthesis, Biological Evaluation, and In Silico Study of N ‐Cinnamamide/Benzamide‐(4‐(Substituted Phenyl)‐6‐(4‐Cyclohexylphenyl)pyrimidin‐2‐yl) Derivatives as EGFR Inhibitors Targeting EGFR WT , EGFR T790M , and EGFR L858R / T790M / C797S in NSCLC. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70390

Vancouver

Pal R, Matada GSP, Teli G, Bv M, Moulishankar A, Chawla V, et al. Rational Design, Synthesis, Biological Evaluation, and In Silico Study of N ‐Cinnamamide/Benzamide‐(4‐(Substituted Phenyl)‐6‐(4‐Cyclohexylphenyl)pyrimidin‐2‐yl) Derivatives as EGFR Inhibitors Targeting EGFR WT , EGFR T790M , and EGFR L858R / T790M / C797S in NSCLC. Chemical Biology & Drug Design. 2026. doi:10.1111/cbdd.70390

BibTeX
@article{Pal2026,
  author = {Pal, Rohit and Matada, Gurubasavaraja Swamy Purawarga and Teli, Ghanshyam and Bv, Manjushree and Moulishankar, Anguraj and Chawla, Viney and Chawla, Pooja A},
  title = {Rational Design, Synthesis, Biological Evaluation, and In Silico Study of N ‐Cinnamamide/Benzamide‐(4‐(Substituted Phenyl)‐6‐(4‐Cyclohexylphenyl)pyrimidin‐2‐yl) Derivatives as EGFR Inhibitors Targeting EGFR WT , EGFR T790M , and EGFR L858R / T790M / C797S in NSCLC},
  journal = {Chemical Biology & Drug Design},
  year = {2026},
  doi = {10.1111/cbdd.70390}
}
Kostenlos starten →